Mannkind

My #1 near term concern was that they were experiencing a participant drop out rate that would invalidate or extend the trials. They provided about as much assurance as they could that this is not going to happen.

The question from Markee (sp) from Griffin Securities sounded like a setup, but I still loved Al's response. I wonder if the poster he referenced who was making positive comments on chat boards is our own affresauser?